Biosimilar use in clinical practice is determined by oncologists’ perceptions of and willingness to prescribe them. The authors investigated US oncologists’ perceptions and use of biosimilars.
Stephanie Fortier, PhD
Advertisement
Articles by Stephanie Fortier, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug
2
New York Experts Push for Coordinated Obesity Care Teams
3
Grocery Assistance Benefit Linked to Fewer Diabetes Complications
4
As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning
5